Structure determination of a potent, selective antibody inhibitor of human MMP9 (GS-5745 bound to M…
Heteromer 40-443
100.0 2×ZN; 2×CA; 1×NCO; Crystal structure of mutant MMP-9 catalytic domain in complex with a twin inhibitor. homo-2-mer 110-444
100 4×ZN; 6×CA; 1×L29; Crystal structure of an MMP twin carboxylate based inhibitor LC20 in complex with the MMP-9 catalyt… homo-2-mer 110-444
100 4×ZN; 6×CA; 1×0ZD; 5×GOL; 6×PGO; 7×PEG; 1×MLT; MMP9 active site mutant-inhibitor complex homo-2-mer 110-443
100 8×CA; 2×STN; 2×BUM; 4×ZN; Dimeric form of the haemopexin domain of MMP9 homo-2-mer 513-707
98.97 4×SO4; Crystal structure of human matrix metalloproteinase MMP9 (gelatinase B). monomer 29-444
99.75 2×ZN; 3×CA; Crystal structure of human proMMP-9 catalytic domain in complex with inhibitor monomer 38-444
100 2×ZN; 3×CA; 1×VP6; 1×2HP; Crystal structure of human proMMP-9 catalytic domain in complex with inhibitor monomer 38-444
100.0 2×ZN; 3×CA; 1×VOC; Crystal structure of human proMMP-9 catalytic domain in complex with inhibitor monomer 38-444
100.0 2×ZN; 3×CA; 1×VOO; Crystal structure of human proMMP-9 catalytic domain in complex with inhibitor monomer 39-444
100.0 2×ZN; 3×CA; 1×VOZ; proMMP-9desFnII complexed to JNJ0966 INHIBITOR monomer 40-443
100.0 2×ZN; 3×CA; 1×SO4; proMMP-9desFnII monomer 41-443
100 2×ZN; 3×CA; 2×SO4; Structure determination of a potent, selective antibody inhibitor of human MMP9 (apo MMP9) monomer 41-443
100.0 2×ZN; 3×CA; Crystal structure of an inactive mutant of MMP-9 catalytic domain in complex with a fluorogenic syn… monomer 107-444
100 1×AZI; 2×ZN; 1×CA; 2×SR; 1×PGO; 2×EDO; 1×PEG; 1×GOL; Crystal structure of an MMP broad spectrum hydroxamate based inhibitor CC27 in complex with the MMP… monomer 107-444
100 2×ZN; 3×CA; 1×10B; 6×GOL; 1×PGO; Crystal structure MMP-9 complexes with a constrained hydroxamate based inhibitor LT4 monomer 107-444
100 2×ZN; 3×CA; 1×LTQ; 2×EDO; 1×PGO; Crystal structure of an inactive mutant of MMP-9 catalytic domain in complex with a fluorogenic syn… monomer 107-444
100 1×AZI; 2×ZN; 2×CA; 1×SR; 5×EDO; 1×GOL; 1×PGO; Crystal structure of an MMP twin inhibitor complexing two MMP-9 catalytic domains monomer 107-444
100 2×ZN; 2×CA; 6×PEG; 3×ACT; 2×BCN; Crystal structure of mutant MMP-9 catalytic domain in complex with a twin inhibitor. monomer 110-444
100 2×ZN; 4×CA; 1×0XX; MMP-9 active site mutant with barbiturate inhibitor monomer 110-443
100 2×ZN; 5×CA; 3×CL; 1×4MR; MMP-9 active site mutant with phosphinate inhibitor monomer 110-443
100 2×ZN; 5×CA; 3×CL; 1×5MR; MMP-9 active site mutant with iodine-labeled carboxylate inhibitor monomer 110-443
100 2×ZN; 4×CA; 4×CL; 1×6MR; MMP-9 active site mutant with trifluoromethyl hydroxamate inhibitor monomer 110-443
100 2×ZN; 4×CA; 3×CL; 1×7MR; MMP9-inhibitor complex monomer 110-443
100 5×CA; 1×NFH; 2×ZN; Crystal structure of MMP9 in complex with inhibitor BE4. monomer 112-444
100 2×ZN; 3×CA; 1×B9Z; 1×PZE; Crystal structure of a hydroxamate based inhibitor EN140 in complex with the MMP-9 catalytic domain monomer 112-444
100 1×E40; 2×ZN; 3×CA; 1×EDO; 2×PGO; 2×PEG; Crystal structure of a hydroxamate based inhibitor ARP101 (EN73) in complex with the MMP-9 catalyti… monomer 113-444
100 1×N73; 2×ZN; 3×CA; 2×DMS; 4×EDO; 1×GOL; 2×PGO; 1×BUD; Crystal structure of the catalytic domain of MMP-9 in complex with a selective sugar-conjugated ary… monomer 113-444
100 2×ZN; 3×CA; 1×H27; 1×EDO; 1×DMS; 1×GOL; MMP-9 active site mutant with difluoro butanoic acid inhibitor monomer 113-443
100 2×ZN; 3×CA; 2×CL; 1×8MR;